T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| 1 |
Broadcom
AVGO
|
+$3.52B |
| 2 |
Boeing
BA
|
+$1.89B |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$1.43B |
| 4 |
Amphenol
APH
|
+$1.1B |
| 5 |
CME Group
CME
|
+$911M |
Top Sells
| 1 |
Apple
AAPL
|
+$3.87B |
| 2 |
Advanced Micro Devices
AMD
|
+$2.1B |
| 3 |
UnitedHealth
UNH
|
+$1.83B |
| 4 |
Uber
UBER
|
+$1.56B |
| 5 |
Adobe
ADBE
|
+$1.29B |
Sector Composition
| 1 | Technology | 33.26% |
| 2 | Healthcare | 12.77% |
| 3 | Consumer Discretionary | 11.7% |
| 4 | Financials | 11.14% |
| 5 | Communication Services | 9.76% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
901
Griffon
GFF
$3.72B
| $28.2M | ﹤0.01% |
395,926
-1,981
| -0.5% | -$141K |
|
902
Akamai
AKAM
$11.4B
| $28.2M | ﹤0.01% |
294,809
-34,312
| -10% | -$3.28M |
|
903
Advanced Energy
AEIS
$6.02B
| $28M | ﹤0.01% |
242,057
-85,210
| -26% | -$9.85M |
|
904
Rush Street Interactive
RSI
$2.05B
| $27.8M | ﹤0.01% |
2,029,239
+2,004,059
| +7,959% | +$27.5M |
|
905
Itaú Unibanco
ITUB
$76.2B
| $27.8M | ﹤0.01% |
6,167,153
-15,335,698
| -71% | -$69.2M |
|
906
Haemonetics
HAE
$2.58B
| $27.7M | ﹤0.01% |
354,281
+25,617
| +8% | +$2M |
|
907
First Advantage
FA
$2.83B
| $27.5M | ﹤0.01% |
1,469,272
+769,825
| +110% | +$14.4M |
|
908
iShares Core S&P 500 ETF
IVV
$675B
| $27.4M | ﹤0.01% |
46,539
+4,134
| +10% | +$2.43M |
|
909
Citizens Financial Group
CFG
$22.3B
| $27.3M | ﹤0.01% |
624,794
-18,162
| -3% | -$795K |
|
910
Essential Properties Realty Trust
EPRT
$5.94B
| $27.3M | ﹤0.01% |
873,983
+50,012
| +6% | +$1.56M |
|
911
LyondellBasell Industries
LYB
$17.8B
| $27.2M | ﹤0.01% |
366,472
+6,945
| +2% | +$516K |
|
912
BridgeBio Pharma
BBIO
$10.1B
| $27.2M | ﹤0.01% |
991,238
+180,773
| +22% | +$4.96M |
|
913
CG Oncology
CGON
$2.53B
| $27.1M | ﹤0.01% |
945,194
+353,787
| +60% | +$10.1M |
|
914
Labcorp
LH
$23.2B
| $27M | ﹤0.01% |
117,837
-328
| -0.3% | -$75.2K |
|
915
Leonardo DRS
DRS
$11.1B
| $27M | ﹤0.01% |
836,293
-1,122,829
| -57% | -$36.3M |
|
916
A10 Networks
ATEN
$1.29B
| $27M | ﹤0.01% |
1,467,993
+37,733
| +3% | +$694K |
|
|
BCAX
917
Bicara Therapeutics Inc. Common Stock
BCAX
$654M
| $27M | ﹤0.01% |
1,547,180
+8,246
| +0.5% | +$144K |
|
918
Factset
FDS
$14B
| $26.6M | ﹤0.01% |
55,296
-91,729
| -62% | -$44.1M |
|
919
LeMaitre Vascular
LMAT
$2.13B
| $26.2M | ﹤0.01% |
284,779
+1,680
| +0.6% | +$155K |
|
920
Dycom Industries
DY
$7.49B
| $25.9M | ﹤0.01% |
148,879
+53,027
| +55% | +$9.23M |
|
921
Seagate
STX
$41.9B
| $25.8M | ﹤0.01% |
299,047
-219,384
| -42% | -$18.9M |
|
922
Olin
OLN
$3.09B
| $25.8M | ﹤0.01% |
761,812
-5,201
| -0.7% | -$176K |
|
|
ORKA
923
Oruka Therapeutics, Inc. Common Stock
ORKA
$605M
| $25.7M | ﹤0.01% |
1,326,893
+1,047,245
| +374% | +$20.3M |
|
924
Invitation Homes
INVH
$18.8B
| $25.6M | ﹤0.01% |
801,119
-3,664
| -0.5% | -$117K |
|
925
10x Genomics
TXG
$1.63B
| $25.6M | ﹤0.01% |
1,781,268
-734,635
| -29% | -$10.5M |
|